Will the sturgeon moon blot out the Perseids? What to know about August's full moon
While the next full moon will reach peak intensity on Aug. 9, the Perseids will offer their light show for several weeks. Viewing may be best this week while the moon is still beginning to wax toward fullness.
Here's what to know about the sturgeon moon in August and how it could impact Perseid viewing.
When will August's full moon peak?
The sturgeon moon will peak in the early morning hours at 3:55 a.m. Aug. 9, 2025.
The moon will appear full the night before, so astronomy buffs can look up into the evening sky Aug. 8 to spot the full moon.
Full moon could disrupt peak Perseids viewing
The Perseids, the year's best meteor shower, is set to peak overnight Aug. 12, three days after the full moon. The full moon will still appear bright, hindering observations of meteors, Robert Lunsford, the American Meteor Society's newsletter editor and fireball report coordinator, told USA TODAY.
Lunsford recommended better viewing chances starting during the new moon, which took place July 24, because the skies will be darker overnight.
One of the best days to watch for meteors will be July 30, because two other meteor showers, alpha Capricornids and Southern delta Aquariids, will be taking place at the same time, according to Lunsford.
How far away from the Earth is the moon?
The average distance between the Earth and the moon is 238,855 miles.
At its farthest from the Earth, the moon is about 252,088 miles away and astronomers say it's at apogee.
When the moon is at perigee, it's 225,623 miles away.
How did the sturgeon moon get its name?
The name sturgeon moon comes from the lake sturgeon, native to the Great Lakes and traditionally a key food source for Indigenous tribes during this summer season, according to the Old Farmer's Almanac.
Michigan is home to lake sturgeon, one of the oldest species on the Great Lakes, though human efforts to eradicate the fish led to a steep decline since the 19th and 20th centuries. Statewide efforts are now working to increase the population with support from state, tribal and federal institutions.
Michigan features an annual sturgeon fishing season on Black Lake in Cheboygan and Presque Isle counties, with the February 2025 season taking just 17 minutes to fill the statewide limit.
What phase of the lunar cycle is the moon in now?
The moon is currently in its waxing crescent phase, at 16% illumination, according to Space.com. The moon's phases in August 2025 are:
First Quarter: Aug. 1
Full Moon: Aug. 9
Last Quarter: Aug. 16
New Moon: Aug. 23
Is the sturgeon moon a supermoon.
No, the sturgeon moon is not a supermoon.
What are the full moon names in 2025?
Here are all the full moons of 2025:
Wolf Moon: January
Snow Moon: February
Worm Moon: March
Pink Moon: April
Flower Moon: May
Strawberry Moon: June
Buck Moon: July
Sturgeon Moon: August
Corn Moon: September
Harvest Moon: October
Beaver Moon: November
Cold Moon: December
When will the corn moon peak?
The corn moon will peak Sept. 7, 2025.
The full moon will feature a total lunar eclipse, though it won't be visible in Michigan, per Space.com.
The Detroit Free Press and USA TODAY contributed.
Contact Jenna Prestininzi: jprestininzi@freepress.com.
This article originally appeared on Detroit Free Press: Sturgeon moon, Perseids to light up Michigan skies in August. Dates, times, viewing locations
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in to access your portfolio
Medscape
an hour ago
- Medscape
Does Chemoradiation Up Second Cancer Risk in Rectal Cancer?
TOPLINE: Among patients with locally advanced rectal cancer, concurrent chemoradiotherapy did not significantly increase second pelvic malignancies compared to chemotherapy alone, but it did raise the risk for nonpelvic cancers. METHODOLOGY: The risk for second cancers after pelvic radiation in patients with locally advanced rectal cancer is unclear, with recent studies yielding conflicting results. To better understand the risk for second malignancies, researchers evaluated 2624 patients with stage II or III rectal cancer who received chemotherapy alone (n = 460) or radiation therapy concurrent with chemotherapy (chemoradiotherapy; n = 2164) between January 1995 and October 2019. Researchers analyzed the cumulative incidence of second malignancies, defined as a new cancer diagnosed more than 2 years after the initial rectal cancer diagnosis. Patients received adjuvant chemotherapy regimens, including FOLFOX (60%), 5-fluorouracil (32%), and capecitabine and oxaliplatin (4%), with median radiation prescription doses of 5040 centigrays for conventional treatments and 5000 centigrays for intensity-modulated radiation therapy. The median follow-up was 6.5 years in the concurrent chemoradiotherapy cohort and 5.6 years in the chemotherapy-alone cohort. TAKEAWAY: Rates of second pelvic malignancies at 10 years were higher with chemoradiotherapy versus chemotherapy, but the differences were not significant: The 10-year cumulative incidence was 5.8% with chemoradiotherapy vs 4.2% with chemotherapy (P = .30). Overall, the most common second pelvic malignancies were prostate adenocarcinoma (31%), bladder cancer (31%), and uterine cancer (28%). The 10-year incidence of second nonpelvic malignancies was significantly higher with chemoradiotherapy: 11% vs 4.4% with chemotherapy alone (P = .017). Overall, the most common second nonpelvic malignancies were lung cancer (24%), breast cancer (15%), and hematologic malignancies (13%). Compared with conventional radiation therapy, intensity-modulated radiation therapy and volumetric modulated arc therapy were associated with a reduced risk for second pelvic malignancies (P = .014). Several factors appeared to impact the risk for second malignancies following treatment. Adults aged 50 and older had higher risks for second pelvic (hazard ratio [HR], 3.03; P = .005) and nonpelvic (HR, 2.48; P < .001) malignancies. Diabetes was linked to an increased risk for second nonpelvic malignancies (HR, 1.51; P = .028), whereas tobacco abstinence was associated with a decreased risk (HR, 0.63; P = .013). IN PRACTICE: O verall, patients who received chemoradiotherapy had a significantly higher cumulative incidence of developing second cancers outside the pelvis but not within the pelvis, the authors concluded. However, 'the concern for radiation-induced second malignancies should not preclude from using [chemoradiotherapy]' in this patient population. Instead, 'these data serve as a foundation for future prospective studies evaluating ways to further reduce the risk of second malignancies in high-risk patients undergoing [chemoradiotherapy] for rectal cancer.' SOURCE: The study, led by Kathryn R. Tringale, MD, and Kush H. Patel of Memorial Sloan Kettering Cancer Center, New York City, was published online in the International Journal of Radiation Oncology, Biology, Physics. LIMITATIONS: Potential surveillance bias existed because patients who received concurrent chemoradiotherapy had more intensive follow-up than those who received chemotherapy alone. Median follow-up was short, and the retrospective design precluded comparing doses in organs at risk that developed second cancers with those that did not. DISCLOSURES: The study was partly funded by a National Institutes of Health/National Cancer Institute grant. Some authors reported receiving research funding and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here's what to expect. Exact Sciences beat analysts' revenue expectations by 2.7% last quarter, reporting revenues of $706.8 million, up 10.9% year on year. It was a satisfactory quarter for the company, with full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Is Exact Sciences a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Exact Sciences's revenue to grow 10.6% year on year to $773.1 million, slowing from the 12.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Exact Sciences has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Exact Sciences's peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Regeneron delivered year-on-year revenue growth of 3.6%, beating analysts' expectations by 11.3%, and Incyte reported revenues up 16.5%, topping estimates by 5.5%. Regeneron traded up 4.8% following the results while Incyte was also up 10.5%. Read our full analysis of Regeneron's results here and Incyte's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the biotechnology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Exact Sciences is down 9.1% during the same time and is heading into earnings with an average analyst price target of $68.55 (compared to the current share price of $47.70). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
